Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

被引:36
|
作者
Pfitzer, C. [1 ]
Orawa, H. [2 ]
Balcerek, M. [1 ]
Langer, T. [3 ]
Dirksen, U. [4 ]
Keslova, P. [5 ]
Zubarovskaya, N. [6 ,7 ]
Schuster, F. R. [8 ]
Jarisch, A. [9 ]
Strauss, G. [1 ]
Borgmann-Staudt, A. [1 ]
机构
[1] Charite, Campus Virchow Klinikum, Dept Paediat Oncol Haematol Stem Cell Transplanta, D-13353 Berlin, Germany
[2] Wissensch Dienste, Berlin, Germany
[3] Erlangen Univ Hosp, Dept Paediat, Dept Immunol & Oncol, Erlangen, Germany
[4] Munster Univ Hosp, Dept Paediat Haematol & Oncol, Munster, Germany
[5] Motol Univ Hosp, Dept Paediat Haematol & Oncol, Prague, Czech Republic
[6] St Anna Childrens Hosp, A-1090 Vienna, Austria
[7] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria
[8] Univ Dusseldorf, Ctr Child & Adolescent Hlth, Fac Med, Clin Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany
[9] Univ Frankfurt Hosp, Dept Haematol, Frankfurt, Germany
关键词
Allogeneic haematopoietic stem cell transplantation; Fertility; Childhood; Gonadotoxic therapy; Recovery; BONE-MARROW-TRANSPLANTATION; GONADAL-FUNCTION; OVARIAN-FUNCTION; BUSULFAN; OUTCOMES; CANCER;
D O I
10.1007/s00432-014-1781-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT. We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005. Development of fertility impairment was observed in males (123/217, 56 %) after a median time of 2.6 years (range 0.1-11.4) and in females (82/144, 57 %) after 2.3 years (range 0.1-12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan a parts per thousand yen16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan < 14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1-10.6) in females (10/144, 7 %) and 2.0 years (range 1-6.3) in males (7/217, 3 %) after fertility impairment first appeared. In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [31] Cardiac biomarkers during and after allogeneic haematopoietic stem cell transplantation
    Roziakova, L.
    Bojtarova, E.
    Mistrik, M.
    Demeckova, E.
    Mladosievicova, B.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S170 - S170
  • [32] Quality of life in patients after allogeneic haematopoietic stem cell transplantation
    Stancheva, N.
    Semenova, E.
    Zubarovskay, N.
    Paina, O.
    Vasilieva, Y.
    Alyansky, A.
    Bagge, D.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S88 - S88
  • [33] Rehabilitation after Allogeneic Haematopoietic Stem Cell Transplantation: A Special Challenge
    Bertz, Hartmut
    CANCERS, 2021, 13 (24)
  • [34] T-CELL RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
    Ligeiro, Dario
    Abecasis, Manuel
    Lima, Alice
    Miranda, Nuno
    Ferreira, Isabelina
    Teixeira, Gilda
    Trindade, Helder
    TISSUE ANTIGENS, 2013, 81 (05): : 302 - 302
  • [35] Efficacy of darbopoietin alfa after allogeneic haematopoietic stem cell transplantation
    Picardi, A
    Spagnoli, A
    Tendas, A
    Mirabile, M
    Cudillo, L
    Dentamaro, T
    Suppo, G
    Amadori, S
    de Fabritiis, P
    BONE MARROW TRANSPLANTATION, 2005, 35 : S103 - S103
  • [36] CMV resistance in patients after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Kouba, M.
    Boutolleau, D.
    Pliskova, L.
    Vejrazkova, E.
    Keslova, P.
    Sedlacek, P.
    Cetkovsky, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S78 - S78
  • [37] CMV genotypes in patiens after allogeneic haematopoietic stem cell transplantation
    Hubacek, P.
    Javornicka, T.
    Sumova, J.
    Keslova, P.
    Kouba, M.
    Zajac, M.
    Markova-Stastna, M.
    Sedlacek, P.
    Cetkovsk, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S410 - S411
  • [38] Pregnancy after allogeneic haematopoietic stem cell transplantation in Fanconi anaemia patients: multi-institution case series of female fertility recovery
    Nabhan, S.
    Bitencourt, M.
    Duval, M.
    Abecasis, M.
    Dufour, C.
    Boudjedir, K.
    Rocha, V.
    Socie, G.
    Passweg, J.
    Goi, K.
    Sanders, J.
    Pasquini, R.
    Gluckman, E.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S58 - S58
  • [39] Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation
    Bergeron, Anne
    Chevret, Sylvie
    de Latour, Regis Peffault
    Chagnon, Karine
    de Margerie-Mellon, Constance
    Riviere, Frederic
    Robin, Marie
    Mani, Jean
    Lorillon, Gwenael
    Socie, Gerard
    Tazi, Abdellatif
    EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (05)
  • [40] Romiplostim in treatment of thrombocytopenia after allogeneic haematopoietic stem cell transplantation
    Uspenskaya, O.
    Lisukov, I.
    Kulagin, A.
    Bondarenko, S.
    Rudakova, T.
    Slesarchuk, O.
    Afanasyev, B.
    Gorbacheva, R. M.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S212 - S212